Bacteriophage Therapy for Difficult-to-Treat Infections: The Implementation of a Multidisciplinary Phage Task Force (<i>The PHAGEFORCE Study Protocol</i>)
In times where only a few novel antibiotics are to be expected, antimicrobial resistance remains an expanding global health threat. In case of chronic infections caused by therapy-resistant pathogens, physicians have limited therapeutic options, which are often associated with detrimental consequenc...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-08-01
|
| Series: | Viruses |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4915/13/8/1543 |
| _version_ | 1797521769394864128 |
|---|---|
| author | Jolien Onsea Saartje Uyttebroek Baixing Chen Jeroen Wagemans Cédric Lood Laura Van Gerven Isabel Spriet David Devolder Yves Debaveye Melissa Depypere Lieven Dupont Paul De Munter Willy E. Peetermans Vera van Noort Maia Merabishvili Jean-Paul Pirnay Rob Lavigne Willem-Jan Metsemakers |
| author_facet | Jolien Onsea Saartje Uyttebroek Baixing Chen Jeroen Wagemans Cédric Lood Laura Van Gerven Isabel Spriet David Devolder Yves Debaveye Melissa Depypere Lieven Dupont Paul De Munter Willy E. Peetermans Vera van Noort Maia Merabishvili Jean-Paul Pirnay Rob Lavigne Willem-Jan Metsemakers |
| author_sort | Jolien Onsea |
| collection | DOAJ |
| description | In times where only a few novel antibiotics are to be expected, antimicrobial resistance remains an expanding global health threat. In case of chronic infections caused by therapy-resistant pathogens, physicians have limited therapeutic options, which are often associated with detrimental consequences for the patient. This has resulted in a renewed interest in alternative strategies, such as bacteriophage (phage) therapy. However, there are still important hurdles that currently impede the more widespread implementation of phage therapy in clinical practice. First, the limited number of good-quality case series and clinical trials have failed to show the optimal application protocol in terms of route of administration, frequency of administration, treatment duration and phage titer. Second, there is limited information on the systemic effects of phage therapy. Finally, in the past, phage therapy has been applied intuitively in terms of the selection of phages and their combination as parts of phage cocktails. This has led to an enormous heterogeneity in previously published studies, resulting in a lack of reliable safety and efficacy data for phage therapy. We hereby present a study protocol that addresses these scientific hurdles using a multidisciplinary approach, bringing together the experience of clinical, pharmaceutical and molecular microbiology experts. |
| first_indexed | 2024-03-10T08:18:14Z |
| format | Article |
| id | doaj.art-10cfd88c81d1491895b43ebb95a74c86 |
| institution | Directory Open Access Journal |
| issn | 1999-4915 |
| language | English |
| last_indexed | 2024-03-10T08:18:14Z |
| publishDate | 2021-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Viruses |
| spelling | doaj.art-10cfd88c81d1491895b43ebb95a74c862023-11-22T10:11:02ZengMDPI AGViruses1999-49152021-08-01138154310.3390/v13081543Bacteriophage Therapy for Difficult-to-Treat Infections: The Implementation of a Multidisciplinary Phage Task Force (<i>The PHAGEFORCE Study Protocol</i>)Jolien Onsea0Saartje Uyttebroek1Baixing Chen2Jeroen Wagemans3Cédric Lood4Laura Van Gerven5Isabel Spriet6David Devolder7Yves Debaveye8Melissa Depypere9Lieven Dupont10Paul De Munter11Willy E. Peetermans12Vera van Noort13Maia Merabishvili14Jean-Paul Pirnay15Rob Lavigne16Willem-Jan Metsemakers17Department of Trauma Surgery, University Hospitals Leuven, 3000 Leuven, BelgiumDepartment of Otorhinolaryngology, University Hospitals Leuven, 3000 Leuven, BelgiumDepartment of Trauma Surgery, University Hospitals Leuven, 3000 Leuven, BelgiumDepartment of Biosystems, Laboratory of Gene Technology, KU Leuven, 3000 Leuven, BelgiumDepartment of Biosystems, Laboratory of Gene Technology, KU Leuven, 3000 Leuven, BelgiumDepartment of Otorhinolaryngology, University Hospitals Leuven, 3000 Leuven, BelgiumPharmacy Department, University Hospitals Leuven, 3000 Leuven, BelgiumPharmacy Department, University Hospitals Leuven, 3000 Leuven, BelgiumDepartment of Intensive Care Medicine, University Hospitals Leuven, 3000 Leuven, BelgiumDepartment of Laboratory Medicine, University Hospitals Leuven, 3000 Leuven, BelgiumDepartment of Pneumology, University Hospitals Leuven, 3000 Leuven, BelgiumDepartment of Internal Medicine, University Hospitals Leuven, 3000 Leuven, BelgiumDepartment of Internal Medicine, University Hospitals Leuven, 3000 Leuven, BelgiumCenter of Microbial and Plant Genetics, KU Leuven, 3000 Leuven, BelgiumLaboratory for Molecular and Cellular Technology, Queen Astrid Military Hospital, 1120 Brussels, BelgiumLaboratory for Molecular and Cellular Technology, Queen Astrid Military Hospital, 1120 Brussels, BelgiumDepartment of Biosystems, Laboratory of Gene Technology, KU Leuven, 3000 Leuven, BelgiumDepartment of Trauma Surgery, University Hospitals Leuven, 3000 Leuven, BelgiumIn times where only a few novel antibiotics are to be expected, antimicrobial resistance remains an expanding global health threat. In case of chronic infections caused by therapy-resistant pathogens, physicians have limited therapeutic options, which are often associated with detrimental consequences for the patient. This has resulted in a renewed interest in alternative strategies, such as bacteriophage (phage) therapy. However, there are still important hurdles that currently impede the more widespread implementation of phage therapy in clinical practice. First, the limited number of good-quality case series and clinical trials have failed to show the optimal application protocol in terms of route of administration, frequency of administration, treatment duration and phage titer. Second, there is limited information on the systemic effects of phage therapy. Finally, in the past, phage therapy has been applied intuitively in terms of the selection of phages and their combination as parts of phage cocktails. This has led to an enormous heterogeneity in previously published studies, resulting in a lack of reliable safety and efficacy data for phage therapy. We hereby present a study protocol that addresses these scientific hurdles using a multidisciplinary approach, bringing together the experience of clinical, pharmaceutical and molecular microbiology experts.https://www.mdpi.com/1999-4915/13/8/1543bacteriophage therapydifficult-to-treat infectionssafetyefficacypatient registry |
| spellingShingle | Jolien Onsea Saartje Uyttebroek Baixing Chen Jeroen Wagemans Cédric Lood Laura Van Gerven Isabel Spriet David Devolder Yves Debaveye Melissa Depypere Lieven Dupont Paul De Munter Willy E. Peetermans Vera van Noort Maia Merabishvili Jean-Paul Pirnay Rob Lavigne Willem-Jan Metsemakers Bacteriophage Therapy for Difficult-to-Treat Infections: The Implementation of a Multidisciplinary Phage Task Force (<i>The PHAGEFORCE Study Protocol</i>) Viruses bacteriophage therapy difficult-to-treat infections safety efficacy patient registry |
| title | Bacteriophage Therapy for Difficult-to-Treat Infections: The Implementation of a Multidisciplinary Phage Task Force (<i>The PHAGEFORCE Study Protocol</i>) |
| title_full | Bacteriophage Therapy for Difficult-to-Treat Infections: The Implementation of a Multidisciplinary Phage Task Force (<i>The PHAGEFORCE Study Protocol</i>) |
| title_fullStr | Bacteriophage Therapy for Difficult-to-Treat Infections: The Implementation of a Multidisciplinary Phage Task Force (<i>The PHAGEFORCE Study Protocol</i>) |
| title_full_unstemmed | Bacteriophage Therapy for Difficult-to-Treat Infections: The Implementation of a Multidisciplinary Phage Task Force (<i>The PHAGEFORCE Study Protocol</i>) |
| title_short | Bacteriophage Therapy for Difficult-to-Treat Infections: The Implementation of a Multidisciplinary Phage Task Force (<i>The PHAGEFORCE Study Protocol</i>) |
| title_sort | bacteriophage therapy for difficult to treat infections the implementation of a multidisciplinary phage task force i the phageforce study protocol i |
| topic | bacteriophage therapy difficult-to-treat infections safety efficacy patient registry |
| url | https://www.mdpi.com/1999-4915/13/8/1543 |
| work_keys_str_mv | AT jolienonsea bacteriophagetherapyfordifficulttotreatinfectionstheimplementationofamultidisciplinaryphagetaskforceithephageforcestudyprotocoli AT saartjeuyttebroek bacteriophagetherapyfordifficulttotreatinfectionstheimplementationofamultidisciplinaryphagetaskforceithephageforcestudyprotocoli AT baixingchen bacteriophagetherapyfordifficulttotreatinfectionstheimplementationofamultidisciplinaryphagetaskforceithephageforcestudyprotocoli AT jeroenwagemans bacteriophagetherapyfordifficulttotreatinfectionstheimplementationofamultidisciplinaryphagetaskforceithephageforcestudyprotocoli AT cedriclood bacteriophagetherapyfordifficulttotreatinfectionstheimplementationofamultidisciplinaryphagetaskforceithephageforcestudyprotocoli AT lauravangerven bacteriophagetherapyfordifficulttotreatinfectionstheimplementationofamultidisciplinaryphagetaskforceithephageforcestudyprotocoli AT isabelspriet bacteriophagetherapyfordifficulttotreatinfectionstheimplementationofamultidisciplinaryphagetaskforceithephageforcestudyprotocoli AT daviddevolder bacteriophagetherapyfordifficulttotreatinfectionstheimplementationofamultidisciplinaryphagetaskforceithephageforcestudyprotocoli AT yvesdebaveye bacteriophagetherapyfordifficulttotreatinfectionstheimplementationofamultidisciplinaryphagetaskforceithephageforcestudyprotocoli AT melissadepypere bacteriophagetherapyfordifficulttotreatinfectionstheimplementationofamultidisciplinaryphagetaskforceithephageforcestudyprotocoli AT lievendupont bacteriophagetherapyfordifficulttotreatinfectionstheimplementationofamultidisciplinaryphagetaskforceithephageforcestudyprotocoli AT pauldemunter bacteriophagetherapyfordifficulttotreatinfectionstheimplementationofamultidisciplinaryphagetaskforceithephageforcestudyprotocoli AT willyepeetermans bacteriophagetherapyfordifficulttotreatinfectionstheimplementationofamultidisciplinaryphagetaskforceithephageforcestudyprotocoli AT veravannoort bacteriophagetherapyfordifficulttotreatinfectionstheimplementationofamultidisciplinaryphagetaskforceithephageforcestudyprotocoli AT maiamerabishvili bacteriophagetherapyfordifficulttotreatinfectionstheimplementationofamultidisciplinaryphagetaskforceithephageforcestudyprotocoli AT jeanpaulpirnay bacteriophagetherapyfordifficulttotreatinfectionstheimplementationofamultidisciplinaryphagetaskforceithephageforcestudyprotocoli AT roblavigne bacteriophagetherapyfordifficulttotreatinfectionstheimplementationofamultidisciplinaryphagetaskforceithephageforcestudyprotocoli AT willemjanmetsemakers bacteriophagetherapyfordifficulttotreatinfectionstheimplementationofamultidisciplinaryphagetaskforceithephageforcestudyprotocoli |